Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$375.33 USD
+2.21 (0.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $374.55 -0.78 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$375.33 USD
+2.21 (0.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $374.55 -0.78 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) rides high on its product and service segments in Q1.
Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance
by Zacks Equity Research
Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.
Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues
by Zacks Equity Research
Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.
Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact
by Zacks Equity Research
Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical (ISRG) posted solid numbers in the third quarter, courtesy of rising customer adoption of procedures and growth in system placements.
This Week's Amazing Earnings Charts
by Tracey Ryniec
Don't look now, but these 5 companies have some of the best earnings track records and charts this week.
Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings?
by Zacks Equity Research
We believe that the growing adoption of Intuitive Surgical's (ISRG) da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the quarter.
Varian Medical Initiates Treatment Using Halcyon System
by Zacks Equity Research
Varian Medical (VAR) has been taking initiatives to gain customers for its broad spectrum of products.
Mazor Robotics Gets CE Mark for Surgical Assurance Platform
by Zacks Equity Research
Earlier this year, Mazor Robotics (MZOR) had announced the receipt of FDA clearance for its Mazor X Align software.
Intuitive Surgical (ISRG) Well Poised on Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
The Zacks Analyst Blog Highlights: Facebook, Air Liquide and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Air Liquide and Intuitive Surgical
Watch Out for the Three Stooges: Global Week Ahead
by John Blank
Q2's biggest earnings week, minutes from the latest FOMC meeting and U.S. GDP Friday may be the Three Musketeers charging markets higher... or, they may become the Three Stooges instead.
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical posted solid numbers in the quarter under review, courtesy of rising customer adoption of procedures and growth in system placements.
Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More
by Zacks Equity Research
The market remained jittery towards medical space due to uncertainties surrounding the future of the healthcare act.
4 Healthcare Megatrends for Investors
by Kevin Cook
One sector combines the best of science and technology with our dreams for healthier and wealthier lives.
Will Intuitive Surgical (ISRG) Surprise in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Why Does Intuitive Surgical Score as a Strong Buy Right Now
by Zacks Equity Research
Over the last three months, Intuitive Surgical Inc. (ISRG) was trading consistently ahead of the S&P 500 Index.
The Fed in the Main Circus Tent: Global Week Ahead
by John Blank
On Wednesday, a two-day Federal Open Market Committee (FOMC) meeting produces a 2 pm ET statement. This will be accompanied by fresh forecasts. Consensus expects a 25 basis point rate hike.
Analyst Reports for GM, VMware and Southwest Airlines
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including General Motors (GM), VMware (VMW), and Southwest Airlines (LUV).
Intuitive Surgical da Vinci X Surgical System Okayed by FDA
by Zacks Equity Research
Headquartered in Sunnyvale, CA, Intuitive Surgical Inc. (ISRG) recently announced that the da Vinci X Surgical System, an upgrade to its flagship da Vinci Xi surgical platform, has been cleared by the FDA.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Sunnyvale, CA-based Intuitive Surgical Inc (ISRG) scaled a new 52-week high of $874.54 on May 19, eventually closing a bit lower at $870.33.
Why Is Intuitive Surgical (ISRG) Up 5.4% Since the Last Earnings Report?
by Zacks Equity Research
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown
by Zacks Equity Research
On Apr 21, we issued an updated research report on Sunnyvale-based Intuitive Surgical (ISRG) -- manufacturer of the da Vinci surgical system (an advanced robot-assisted surgical system) and related instruments and accessories.
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.